BiotechTube

Recombinant Interferon Alfa-2b + Rintatolimod

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematopoietic and Lymphoid Cell Neoplasm

Conditions

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed

Trial Timeline

Nov 17, 2020 → Mar 15, 2023

NCT ID
NCT04379518

About Recombinant Interferon Alfa-2b + Rintatolimod

Recombinant Interferon Alfa-2b + Rintatolimod is a phase 1/2 stage product being developed by AIM ImmunoTech for Hematopoietic and Lymphoid Cell Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT04379518. Target conditions include Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04379518Phase 1/2Terminated

Competing Products

20 competing products in Hematopoietic and Lymphoid Cell Neoplasm

See all competitors
ProductCompanyStageHype Score
ASP0113Astellas PharmaPhase 2
52
Itacitinib + CorticosteroidJohnson & JohnsonPhase 2
52
Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + LinezolidMerckPhase 2
52
caspofungin + liposomal amphotericin BMerckPhase 2
52
Efprezimod alfa + Placebo + Methotrexate + TacrolimusMerckPhase 3
77
Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + UprosertibNovartisPhase 1/2
41
ICL670NovartisApproved
85
Blinatumomab + Dexamethasone + Ibrutinib + NivolumabAmgenPhase 2
51
DenosumabAmgenPhase 2
51
RemdesivirGilead SciencesPhase 2
51
Inotuzumab Ozogamicin + Vincristine Sulfate LiposomePfizerPhase 1/2
40
SAR302503Bristol Myers SquibbPhase 2
51
SAR302503 + PlaceboBristol Myers SquibbPhase 3
76
SAR302503Bristol Myers SquibbPhase 2
51
SAR302503Bristol Myers SquibbPhase 2
51
NarsoplimabOmeros CorporationPre-clinical
18
SARS-CoV-2 mRNA Vaccine ARCT-021 + TozinameranArcturus TherapeuticsPhase 2
44
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 PlaceboSeres TherapeuticsPhase 1
25
BL-8040 + PlaceboBioLineRxPhase 1
25
human lactoferrin peptide 1-11AM-PharmaPhase 1/2
33

Other Products from AIM ImmunoTech

AmpligenPhase 3
69
Alferon LDOPhase 2
44
poly I-poly C12UPhase 2
44
EC Aspirin + Recombinant Interferon Alfa-2b + RintatolimodPhase 2
44
poly I-poly C12UPhase 2
44